President Trump threatened to levy a new 50% tariff on E.U.-imported goods last week. Novo Nordisk manufactures much of its GLP-1 drugs in Denmark. The president delayed implementation of the ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy and Ozempic, according to Danish media Finans. Novo’s women are paid ...

Shares of Ozempic and Wegovy manufacturer Novo Nordisk (NYSE: NVO) reacted positively to the news and are up 4.9% as of 10:20 a.m. ET. Where to invest $1,000 right now? Our analyst team just ...

It isn't wise to count out this veteran pharmaceutical company, however. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why.

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names ...

Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks. I believe this is due to the strong performance of its GLP-1 products ...

It's been a tough year for Novo Nordisk, the Danish pharmaceutical company behind the GLP-1 drugs Ozempic and Wegovy. Competitors are nipping at its heels, cheaper knockoffs have been eating into ...

Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo Nordisk for support. The ADA’s obesity division went live last June ...

Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight ...

“The legal tangle over Novo Nordisk’s weightloss and diabetes drug semaglutide will be a “test case” of sorts, say intellectual property (IP) experts, as more Indian drugmakers wait in the ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. When Lars Fruergaard Jørgensen came down the grand circular staircase at Novo Nordisk’s headquarters ...